In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease

  • Masamichi Yokokura
  • Norio Mori
  • Shunsuke Yagi
  • Etsuji Yoshikawa
  • Mitsuru Kikuchi
  • Yujiro Yoshihara
  • Tomoyasu Wakuda
  • Genichi Sugihara
  • Kiyokazu Takebayashi
  • Shiro Suda
  • Yasuhide Iwata
  • Takatoshi Ueki
  • Kenji J. Tsuchiya
  • Katsuaki Suzuki
  • Kazuhiko Nakamura
  • Yasuomi Ouchi
Original Article

Abstract

Purpose

Amyloid β protein (Aβ) is known as a pathological substance in Alzheimer’s disease (AD) and is assumed to coexist with a degree of activated microglia in the brain. However, it remains unclear whether these two events occur in parallel with characteristic hypometabolism in AD in vivo. The purpose of the present study was to clarify the in vivo relationship between Aβ accumulation and neuroinflammation in those specific brain regions in early AD.

Methods

Eleven nootropic drug-naïve AD patients underwent a series of positron emission tomography (PET) measurements with [11C](R)PK11195, [11C]PIB and [18F]FDG and a battery of cognitive tests within the same day. The binding potentials (BPs) of [11C](R)PK11195 were directly compared with those of [11C]PIB in the brain regions with reduced glucose metabolism.

Results

BPs of [11C](R)PK11195 and [11C]PIB were significantly higher in the parietotemporal regions of AD patients than in ten healthy controls. In AD patients, there was a negative correlation between dementia score and [11C](R)PK11195 BPs, but not [11C]PIB, in the limbic, precuneus and prefrontal regions. Direct comparisons showed a significant negative correlation between [11C](R)PK11195 and [11C]PIB BPs in the posterior cingulate cortex (PCC) (p < 0.05, corrected) that manifested the most severe reduction in [18F]FDG uptake.

Conclusion

A lack of coupling between microglial activation and amyloid deposits may indicate that Aβ accumulation shown by [11C]PIB is not always the primary cause of microglial activation, but rather the negative correlation present in the PCC suggests that microglia can show higher activation during the production of Aβ in early AD.

Keywords

Alzheimer’s disease Microglia Amyloid β protein Positron emission tomography 

Notes

Acknowledgments

We would like to thank Dr. Mitsuo Kaneko (Kaneko Clinic), Dr. Masanobu Sakamoto and Messrs. Toshihiko Kanno and Yasuo Tanizaki (Hamamatsu Medical Center), Yutaka Naito (Japan Environment Research Corporation), Masami Futatsubashi, Akihito Oda and Ms. Tomomi Shinke (Hamamatsu Photonics KK) for their support. This work was supported by Research Grants from the Japanese Ministry of Health, Labor and Welfare, and Ministry of Economy, Trade and Industry, and NEDO and the Takeda Science Foundation.

Conflicts of interest

None.

Supplementary material

259_2010_1612_MOESM1_ESM.doc (62 kb)
Supplementary Table 1Results of SPM analysis (DOC 61 kb)
259_2010_1612_MOESM2_ESM.doc (66 kb)
Supplementary Table 2Pearson correlation analyses in the AD group (DOC 65 kb)

References

  1. 1.
    Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006;12:1005–15.PubMedGoogle Scholar
  3. 3.
    Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer’s mice. Nat Neurosci 2002;5:1288–93.CrossRefPubMedGoogle Scholar
  4. 4.
    Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999;286:2352–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen K, Iribarren P, Hu J, Chen J, Gong W, Cho EH, et al. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem 2006;281:3651–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Richard KL, Filali M, Préfontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. J Neurosci 2008;28:5784–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006;129:3006–19.CrossRefPubMedGoogle Scholar
  8. 8.
    Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358:461–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006;129:2856–66.CrossRefPubMedGoogle Scholar
  10. 10.
    Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009;73:1186–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19.CrossRefPubMedGoogle Scholar
  12. 12.
    Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007;68:501–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease. Neuroimage 2008;39:619–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Jack Jr CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 2009;132:1355–65.CrossRefPubMedGoogle Scholar
  15. 15.
    Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2005;2:22.CrossRefPubMedGoogle Scholar
  16. 16.
    Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 2006;103:5161–6.CrossRefPubMedGoogle Scholar
  17. 17.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.PubMedGoogle Scholar
  18. 18.
    Ouchi Y, Nobezawa S, Okada H, Yoshikawa E, Futatsubashi M, Kaneko M. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology 1998;51:136–42.PubMedGoogle Scholar
  19. 19.
    Watanabe M, Shimizu K, Omura T, Takahashi M, Kosugi T, Yoshikawa E, et al. A new high-resolution PET scanner dedicated to brain research. IEEE Trans Nucl Sci 2002;49:634–9.CrossRefGoogle Scholar
  20. 20.
    Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123:2321–37.CrossRefPubMedGoogle Scholar
  22. 22.
    Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 2005;57:168–75.CrossRefPubMedGoogle Scholar
  23. 23.
    Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959–72.PubMedGoogle Scholar
  25. 25.
    Talairach J, Tournoux P. Co-planer stereotaxic atlas of the human brain: 3-dimensional proportional system: an approach to cerebral imaging. Stuttgart: Thieme; 1988.Google Scholar
  26. 26.
    Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson’s disease: compartment analysis for beta-CFT binding with positron emission tomography. Ann Neurol 1999;45:601–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 2008;32:412–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009;66:60–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Någren K, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008;65:1304–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94.CrossRefPubMedGoogle Scholar
  31. 31.
    Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer’s disease. Alzheimers Dement 2008;4:S29–36.CrossRefPubMedGoogle Scholar
  32. 32.
    Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry 2002;159:738–45.CrossRefPubMedGoogle Scholar
  33. 33.
    Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci 2007;27:796–807.CrossRefPubMedGoogle Scholar
  34. 34.
    Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008;14:837–42.CrossRefPubMedGoogle Scholar
  35. 35.
    Malaplate-Armand C, Florent-Béchard S, Youssef I, Koziel V, Sponne I, Kriem B, et al. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol Dis 2006;23:178–89.CrossRefPubMedGoogle Scholar
  36. 36.
    Szczepanik AM, Rampe D, Ringheim GE. Amyloid-beta peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J Neurochem 2001;77:304–17.CrossRefPubMedGoogle Scholar
  37. 37.
    Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997;388:878–81.CrossRefPubMedGoogle Scholar
  38. 38.
    McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990;335:1037.CrossRefPubMedGoogle Scholar
  39. 39.
    Mackenzie IR. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation. Neurobiol Aging 2001;22:819–22.CrossRefPubMedGoogle Scholar
  40. 40.
    Craft JM, Watterson DM, Frautschy SA, Van Eldik LJ. Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol Aging 2004;25:1283–92.CrossRefPubMedGoogle Scholar
  41. 41.
    Rosi S, Ramirez-Amaya V, Vazdarjanova A, Esparza EE, Larkin PB, Fike JR, et al. Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine. Brain 2009;132:2464–77.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Masamichi Yokokura
    • 1
  • Norio Mori
    • 1
  • Shunsuke Yagi
    • 2
  • Etsuji Yoshikawa
    • 3
  • Mitsuru Kikuchi
    • 4
  • Yujiro Yoshihara
    • 1
  • Tomoyasu Wakuda
    • 1
  • Genichi Sugihara
    • 5
  • Kiyokazu Takebayashi
    • 1
  • Shiro Suda
    • 5
  • Yasuhide Iwata
    • 1
  • Takatoshi Ueki
    • 6
  • Kenji J. Tsuchiya
    • 5
  • Katsuaki Suzuki
    • 5
  • Kazuhiko Nakamura
    • 1
  • Yasuomi Ouchi
    • 2
  1. 1.Department of Psychiatry and NeurologyHamamatsu University School of MedicineHamamatsuJapan
  2. 2.Laboratory of Human Imaging Research, Molecular Imaging Frontier Research CenterHamamatsu University School of MedicineHamamatsuJapan
  3. 3.Central Research LaboratoryHamamatsu Photonics K.K.HamamatsuJapan
  4. 4.Department of Psychiatry and Neurobiology, Graduate School of Medical ScienceKanazawa UniversityKanazawaJapan
  5. 5.Research Center for Child Mental DevelopmentHamamatsu University School of MedicineHamamatsuJapan
  6. 6.Department of AnatomyHamamatsu University School of MedicineHamamatsuJapan

Personalised recommendations